Skip to Content, Navigation, or Footer.
The Daily Cardinal Est. 1892
Thursday, June 08, 2023
News_ PsychoactiveMushrooms.jpg

UW to offer masters degree in psychoactive drugs

The UW-Madison School of Pharmacy is launching a master’s degree program in psychedelic drug therapy in the fall of 2021, the first of its kind in the nation. 

The fully-online Psychoactive Pharmaceutical Investigation program will look to examine the relationships between psychedelic drugs and mental health, including MDMA, also known as ecstasy; psilocybin, the active ingredient in mushrooms; ketamine and more. 

Many of the drugs studied in the program fall under the Schedule 1 classification, meaning they are banned for medical use and are highly addictive, according to the Drug Enforcement Administration.

However, the therapeutic drug sector is expected to grow by 20% per decade. According to UW News, the market will be worth about $100 billion by 2030. 

“This master’s program was designed in collaboration with external partners to ensure that graduates will leave the program with real-world knowledge and in-demand job skills,” Director of the Psychoactive Pharmaceutical Investigation program Cody Wenthur said in a press release. “The scope of the psychedelic research ‘renaissance’ is rapidly expanding beyond academic research.”

These drugs have been tied to relieving problems including depression, post-traumatic stress disorder and other mental health disorders, according to the Wisconsin State Journal.  

“Anything that can help reverse those extremely worrisome outcomes will be met with a great deal of enthusiasm,” Wenthur said.

Currently, the Food and Drug Administration has designated psilocybin as a “breakthrough therapy” drug to treat depression and MDMA to treat PTSD.

UW-Madison has already made breakthroughs in psychedelic drug treatments, as the university is currently a research site for a Phase 2 study of psilocybin mushrooms to treat depression and a Phase 3 study of MDMA to treat post-traumatic stress disorder

UW Health also currently uses ketamine therapy to treat depression.  

The program begins in 2022 and will offer a 1-year accelerated option. Students will also be able to complete a 12-credit capstone certificate in Psychoactive Pharmaceutical Investigation. Doctor of Pharmacy students will also have the ability to complete courses in the subject. 

Enjoy what you're reading? Get content from The Daily Cardinal delivered to your inbox
Support your local paper
Donate Today
The Daily Cardinal has been covering the University and Madison community since 1892. Please consider giving today.

Powered by SNworks Solutions by The State News
All Content © 2023 The Daily Cardinal